Arbutus Biopharma Corp (ABUS) company profile
Close on Nov 12, 2026Market cap $797.33MP/E 3.6Yield –
About Arbutus Biopharma
Pharmaceutical Preparations, SIC 2834
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on therapies for infectious diseases, specifically chronic hepatitis B. Its pipeline features imdusiran, a subcutaneously administered ribonucleic acid interference drug, and AB-101, an oral checkpoint inhibitor intended to restore immune function. The company also licenses its proprietary lipid nanoparticle delivery technology to external partners. Its medical candidates target patients diagnosed with chronic hepatitis B, while its delivery platforms serve biopharmaceutical collaborators.
The company historically maintained corporate headquarters in Warminster, Pennsylvania, before deciding to exit the site and end internal laboratory research. Its clinical activities encompass trials that have dosed more than two hundred study subjects across early-stage programs. Arbutus retains complete worldwide commercial rights for imdusiran following the termination of an alliance covering China, Hong Kong, Macau, and Taiwan. It also holds an equity stake in Genevant and engages in licensing arrangements across the United States and international markets.
Summary of the business section of Arbutus Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Arbutus Biopharma Corp
- Founded
- 2007
- Headquarters
- Warminster, PA
- Address
- 701 Veterans Circle 18974
- Phone
- (604) 419-3200
- Website
- arbutusbio.com
- Employees
- 19, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- ABUS
- Exchange
- Nasdaq
- IPO date
- Jul 26, 2007
- Shares outstanding
- 198M, Aug 10, 2026
- Public float
- $472.13M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-5 reverse, Nov 4, 2010
- SEC CIK
- 1447028
- CUSIP
- 03879J100
- ISIN
- CA03879J1003
- FIGI
- BBG000RR8V85
- Share class FIGI
- BBG001S6RSK0
- LEI
- 25490064CESONAUIAS23
- EIN
- 98-0597776
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lindsay Androski | President and CEO, Director | 47,682 |
| Michael J. McElhaugh | Interim President & CEO, Director | 1,658,003 |
| Tuan Nguyen | Chief Financial Officer | 111,882 |
| J. Christopher Naftzger | General Counsel and CCO | 140,544 |
| Karen Sims | Chief Medical Officer | 155,494 |
| David C. Hastings | Chief Financial Officer | 249,824 |
| Roger Sawhney | Director | 13,683 |
| Robert A. Beardsley | Director | 14,328 |
| Sciences Ltd. Roivant | Director | 29,880,079 |
| Anuj Hasija | Director | – |
| Matthew Gline | Director | 38,847,462 |
| Joseph E. Bishop | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr Mc Elhaugh | $3.58M | $1.15M | $2.32M | $206 | – |
| FY2025 Ms Androski | $1.37M | $1.66M | $2.32M | $206 | – |
| FY2024 Mr Mc Elhaugh | $2.11M | $2.59M | $1.78M | $140 | – |
| FY2024 Ms Androski | $0 | $0 | $1.78M | $140 | – |
| FY2023 Ms Androski | $0 | $0 | $1.69M | $107 | – |
| FY2023 William Collier | $3.39M | $3.27M | $1.69M | $107 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Lindsay Androski President and Chief Executive Officer | $437.75K | – | $714.75K | $216.51K | – | $1.37M | – |
| Tuan Nguyen Chief Financial Officer | $359.85K | – | $1.88M | $159.76K | $17.50K | $2.42M | – |
| Michael McElhaugh Former Interim President and Chief Executive Officer | $109.66K | $582.33K | $1.86M | – | $1.03M | $3.58M | +70% |
| David C. Hastings Former Chief Financial Officer | $138.61K | $296.43K | $944.27K | – | $839.05K | $2.22M | +21% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 19 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 23, 2019 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 16, 2017 | Late filing | Notification of late filing |
| Sep 28, 2016 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 3, 2015 | Name change | Name changed from TEKMIRA PHARMACEUTICALS Corp to Arbutus Biopharma Corp |
| Mar 4, 2015 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 4, 2015 | Merger vote | Definitive merger proxy statement |
| Nov 4, 2010 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?